Zenta Tsuchihashi
Senior Director, Translational Patient Safety, Clinical Safety & Pharmacovigilance Daiichi Sankyo
Zenta Tsuchihashi is Senior Director and Head of Translational Safety, Clinical Safety, and Pharmacovigilance at Daiichi Sankyo. He leads translational research focused on safety across the oncology portfolio, including work on drug-induced interstitial lung disease and antibody-drug conjugate safety. Previously, he served as Translational Science Lead for DS-8201 (ENHERTU), advancing biomarker development and translational strategies in oncology. Before Daiichi Sankyo, he held leadership roles at AstraZeneca, Novartis, and Bristol-Myers Squibb, contributing to biomarker discovery and clinical development across multiple cancer programs. With more than two decades in pharmaceutical research, he has extensive experience in translational science, biomarker development, and oncology drug development.
Seminars
As ADC development continues to expand across increasingly diverse targets, payloads, and antibody formats,
understanding which molecular and physicochemical properties most strongly influence safety is critical to widening the
therapeutic window. This panel will explore which variables can be modulated to improve safety and how mechanistic insights
can be translated into smarter candidate selection by:
- Identifying the most critical determinants of ADC safety by examining how payload characteristics, antibody properties, conjugation parameters, and overall molecular design contribute to off-target toxicity and therapeutic window
- Exploring how payload and antibody properties can be strategically modulated by assessing the impact of payload physicochemical characteristics, Fc-mediated interactions, non-specific uptake mechanisms, and other molecular features on ADC distribution, cellular uptake, and toxicity
- Debating emerging strategies to improve ADC safety by design including Fc-silencing, alternative antibody formats, bispecific and biparatopic approaches, masked antibodies, and other engineering technologies, while considering how these approaches can translate mechanistic understanding into improved candidate selection and clinical safety
